Across TCGA pan-cancer cohorts, STK40 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STK40 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher STK40 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STK40 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, CHOL, and BLCA are the cancer types where STK40 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.084	0.844	<.001	36	view →
CHOL	OS	Median	All	0.019	0.800	<.001	24	view →
BLCA	OS	Median	All	0.193	0.720	.002	21	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
UCEC	DFS	Median	II,III,IV	0.906	0.441	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: STK40 tumor-vs-normal RNA expression · all STK40 data types